BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust


1/28/2009 10:02:56 AM

CAMBRIDGE, England, January 28 /PRNewswire/ -- Phico Therapeutics today announced it has been granted a Wellcome Trust Strategic Translational Award totalling GBP1.03 million to cover Phase I and II trials of its lead candidate SASPject(TM) PT1.2 for nasal decolonisation of MRSA and S. aureus. PT1.2 is based on a new class of antibacterial proteins called SASPs which bind to bacterial DNA resulting in rapid "speed of kill". Phico envisages developing a fast-acting, easily applicable nasal gel which would combat both hospital S. aureus infection and hospital and community MRSA transmission and drug-resistance.

According to Phico Therapeutics CEO and founder, Dr Heather Fairhead, there is a clear need for such a product. "Whilst hospitals have introduced stricter cleaning regimes, the twin problems of transmission and drug-resistance remain. We already demonstrated last year in several studies, including some carried out in conjunction with the UK's Health Protection Agency, that PT1.2 is rapidly bactericidal against more than 200 clinical S. aureus and MRSA isolates, spanning the known MRSA types in Europe and the US. Indeed in the speed of kill assay, SASP caused a greater than or equal to 99.9 % drop in viability within 2 minutes against a 10(5) culture and a greater than or equal to 99.9 % drop in viability within 10 minutes against a 10(7) culture of a major US MRSA strain. I am delighted that the Wellcome Trust see the potential of PT1.2. This award will enable us to conduct phase I and II clinical trials with results expected Q3 2009 and Q3 2010 respectively."

Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust commented: "There is an urgent need to develop innovative ways to manage the transmission of antibiotic-resistant bacteria in the hospital and care-home environments. The approach being taken by Dr Fairhead and colleagues is imaginative and original. If successful, this technology may provide an important new tool in the fight against MRSA and other pathogenic bacteria."

Dr Fairhead also added that other SASP candidates in the Company's pipeline are being developed against C. difficile and E. coli/Klebsiella pneumoniae, and a modified PT1.2 is being developed for intravenous use and that she would be seeking further funding to advance their development.

CONTACT: Corporate Enquiries, Heather Fairhead, CEO, Tel:
+44(0)1223-496562, Email: hf@phicotherapeutics.co.uk; Media enquiries,
Richard Hayhurst, Hayhurst Media, Tel: +44(0)7711-821527, Email:
richard@hayhurstmedia.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES